INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Trial ID or NCT#
NCT04295759
Status
RECRUITING
Purpose
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.
Official Title
A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
Eligibility Criteria
Ages Eligible for Study: 3 Years to 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Michelle Monje
Contact us to find out if this trial is right for you.
Contact
Erica Velasco
650-721-4083
View on ClinicalTrials.gov
